We are pleased to announce that OCRA’s Chief Program Officer, Sarah DeFeo, has been awarded the inaugural Andrew Godwin Award for Excellence in Community Outreach. Presented by Ovarian Cancer Midwest … Continued
A sea of teal washed over the Capitol when more than 70 advocates from 30 states met with over 120 Congressional offices to push for legislative initiatives, including Medicare coverage … Continued
Madeleine and Emma Jean may be young, at ages eight and nine, respectively, but they are already focused on how to help create a future in which no families are … Continued
OCRA’s National Conference begins November 1st Join us virtually from November 1st – 3rd for three days of information, community and resources. Attendees will learn the latest updates in research, … Continued
Participants in OCRA’s virtual support programs came together for a face-to-face meetup in Chicago this weekend, deepening community connections and highlighting the importance of support programs for those with shared … Continued
OCRA’s Ovarian Cycle Tampa event was in the news this week, shining a well-deserved light on the event’s riders and organizers, and what inspires them to participate in OCRA’s signature … Continued
OCRA Announces Game-Changing Initiatives This month, OCRA announced a trio of initiatives that carry profound implications for ovarian cancer and related research and patient support: OCRA will expand its mission to include … Continued
New York, NY, September 26, 2023 — As Ovarian Cancer Awareness Month draws to a close, Ovarian Cancer Research Alliance (OCRA) is announcing a trio of initiatives that carry profound implications for ovarian … Continued
Snap Summary: Research co-funded by OCRA found that foregoing genetic counseling before and after genetic testing does not negatively impact individuals who do not have a pathogenic mutation. Studies have … Continued
Snap Summary: An OCRA-funded study sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant … Continued
OCRA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. We’re proud to receive the highest possible rating from Charity … Continued
OCRA’s important message urging genetic testing and consideration of prophylactic action to reduce risk of ovarian cancer has received a significant boost from various media outlets, including Yahoo! Finance and … Continued
Get email updates about research news, action alerts, and ways to join the fight.
